The European Medicines Agency’s Committee for Medicinal Products for Human recommends eight new medicines for approval, alongside 13 extensions of indication for existing medicines.
Among the headline recommendations at EMA’s Committee for Medicinal Products for Human Use (CHMP) meeting were three new treatments and one orphan medicine.
Lung fibrosis
Jascayd (nerandomilast), from Boehringer Ingelheim, for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) received a positive opinion IPF and PPF affects more than 500,000 people across the EU.
“Current treatments for IPF and PPF, including in patients whose PPF is associated with underlying…
